The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease Endpoints News…
Read More »Endpoints
Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug Endpoints News A once-yearly PrEP? Gilead’s…
Read More »Anthos’ detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer’s failed? Endpoints News Anthos spells out benefits…
Read More »GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk? Endpoints News Obesity drugs: huge study identifies…
Read More »